|  |
| --- |
| Supplement Table 4 The prediction of response to immunotherapy between low and high expression group of TBX5-AS1 in LIHC, UCEC and GBM cohorts. |
| Cancer Type | Immunotherapy | IPS values (Low expression) | IPS values (High expression) | P values |
| LIHC | PD1 inhibitors | 6.982 | 7.408 | 0.0146 |
| CTLA-4 blockers | 7.945 | 8.34 | 0.0089 |
| Combination theraoy | 6.618 | 6.984 | 0.0425 |
| UCEC | PD1 inhibitors | 7.452 | 7.872 | 0.0012 |
| CTLA-4 blockers | 6.57 | 6.863 | 0.0384 |
| Combination theraoy | 6.065 | 6.390 | 0.0344 |
| GBM | PD1 inhibitors | 6.179 | 6.414 | 0.4109 |
| CTLA-4 blockers | 6.607 | 6.724 | 0.6530 |
| Combination theraoy | 5.286 | 5.621 | 0.2885 |